## Abstract ## BACKGROUND: Risk models to predict prostate cancer on biopsy, whether they include only prostate‐specific antigen (PSA) or other markers, are intended for use in all men of screening age. However, the association between PSA and cancer probably depends on a man's recent screening hi
Nomogram use for the prediction of indolent prostate cancer : Impact on screen-detected populations
✍ Scribed by Stijn Roemeling; Monique J. Roobol; Michael W. Kattan; Theo H. van der Kwast; Ewout W. Steyerberg; Fritz H. Schröder
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 69 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND
Screening for prostate cancer has resulted in an increased incidence‐to‐mortality ratio. Not all cancers deserve immediate treatment. It has therefore become more important to be able to identify those cases of screen‐detected prostate cancer most likely to show indolent behavior.
METHODS
The Kattan‐nomogram for the prediction of indolent prostate cancer was validated and recalibrated for use in a screening setting. The recalibrated nomogram was used to calculate the number of men who were predicted to have indolent cancer in a screen‐detected cohort from the European Randomized study of Screening for Prostate Cancer (ERSPC), section Rotterdam.
RESULTS
Of 1629 cancers detected in 2 subsequent screening rounds 825 were suitable for nomogram use. The remainder were very unlikely to have indolent cancer. A total of 485 men (485 of 825 = 59%) were predicted to have indolent cancer, which is 30% (485 of 1629) of all screen‐detected cases. Cancers found at repeated screening after 4 years had a higher probability of indolent cancer than cases from the prevalence screening (44% vs 23%; P < .001).
CONCLUSIONS
The current nomogram can identify substantial groups of screen‐detected cancers that are likely indolent and can therefore be considered for active surveillance. Cancer 2007. © 2007 American Cancer Society.
📜 SIMILAR VOLUMES
## Abstract This study reports the outcome of active surveillance in men with PSA screening‐detected prostate cancer (PC), and PSA doubling time (PSADT) was evaluated as a predictor of selecting patients to active treatment or surveillance. On December 31, 1994, 10,000 men were randomized to bienni
## Abstract ## BACKGROUND. A correlation between prostate specific antigen (PSA) level and positive prostate biopsy rate was established in an era when biopsy practice patterns were different from what they are today. We evaluated if changes in biopsy practice patterns have affected the ability of
## Abstract ## Purpose To evaluate the usefulness of the wash‐in rate based on dynamic contrast‐enhanced (DCE) MRI for the detection and localization of prostate cancer. ## Materials and Methods In 53 patients, the wash‐in rate was measured in the cancer area and in three normal areas (the perip